| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | OSI-930 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.4 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.4 |
| mRNA | EX-527 | GDSC1000 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | 0.042 | 0.4 |
| mRNA | selumetinib:BRD-A02303741 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |